Swiss biotech company Rejuveron raises $75 million in a Series B for expansion in MENA

Rejuveron is a clinical-stage biotechnology company creating therapies to improve healthy aging. Here are details of Rejuveron’s latest funding round :

🚀 Launch

2019

🏭 Industry

Biotechnology

🧠Management

Christian Angermayer, Matthias Steger, Aksana Labokha, Manuel Serrano, Timothy Cash, Lee Rubin, Tristan Heintz, Marianna Feretzaki, Naffi Wade, Malaika Schroeder

💸 Funding & Investors

  • Investment (September 2023) : $75 million (Series B)
  • Investors : co-led by Catalio Capital Management and Apeiron Investment Group, the family office and private investment firm of entrepreneur Christian Angermayer. The round was also joined by new investor Mubadala Capital, a subsidiary of Mubadala Investment Company.

🎯 Funding purpose

Investment in Boost Neuroscience, a Catalio-backed company developing brain synapse regeneration technologies. And expansion in the Middle East.

🌐 Country HQ

UK

Leave a Reply

Your email address will not be published. Required fields are marked *